Gravity Analytica

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results

SRPT 10.23.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-06

Name of Upcoming Event:Sarepta's Third Quarter 2024 Financial Results Conference Call

Full Press Release SEC Filings Our SRPT Tweets

About Gravity Analytica

Recent Filings

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 23, 2024--Sarepta Therapeutics, Inc.(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2024 financial results after the Nasdaq Global Market closes onWednesday, Nov. 6, 2024. Subsequently, at4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2024 financial results.

The event will be webcast live under the investor relations section of Sarepta's website athttps://investorrelations.sarepta.com/events-presentationsand following the event a replay will be archived there for one year. Interested parties participating by phone will need to register usingthis online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

AboutSarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visitwww.sarepta.comor follow us onLinkedIn,X (formerly Twitter),InstagramandFacebook.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website atwww.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241023549080/en/

Investor:Ian Estepan, 617-274-4052iestepan@sarepta.com

Media:Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com

Source:Sarepta Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com